ResApp Health : Quarterly Activities Report and Appendix 4C

For personal use only

Quarterly Activities Report

For the period ending 31 March 2022

• § ResAppDx launched on Alodokter (Indonesia) and Doctors on Demand (Australia) telehealth platforms

• § New ResAppDx customer agreements with Homify (Philippines), Health Teams (Australia) and Dartford and Gravesham NHS Trust (UK)

• § Positive results for an instant COVID-19 screening test requiring only a smartphone

• § Proposed acquisition of ResApp by Pfizer at a price of $0.115 per share in cash

• § Research and development license with Pfizer, including a $3 million upfront fee and up to $1 million in milestone payments

• § Quarterly customer receipts increased 44% to $178,000 (Q2: $124,000)

Brisbane, Australia, 26 April 2022 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to provide an activities update for the three month period ended 31 March 2022 ("Q3 FY2022").

OPERATIONAL HIGHLIGHTS

ACUTE RESPIRATORY DIAGNOSIS

Continued broader use of ResAppDx in telehealth

In January, Alodokter, Indonesia's largest telehealth provider, launched ResAppDx, ResApp's acute respiratory disease diagnostic test, on their telehealth platform. ResAppDx also went live on Doctors on Demand's telehealth platform in Australia.

During the quarter, ResApp signed a binding letter of intent (LOI) with the Philippines-based telehealth start-up, Homify, which plans to launch ResAppDx on its platform in the middle of calendar year 2022. ResApp secured regulatory approval in the Philippines for ResAppDx during the quarter. The LOI is conditional upon Homify achieving certain milestones, including securing the necessary regulatory and legal approvals to operate a telehealth business in the Philippines.

In February, ResApp signed a two-year non-exclusive agreement with Australian aged-care patient monitoring platform provider, Health Teams. Health Teams plans to use ResAppDx on both its telehealth platform and for in-room patient consultations.

In April, ResApp signed a one-year agreement with the Dartford and Gravesham National Health Service (NHS) Trust to pilot ResAppDx across its four hospitals. The pilot is expected to commence in the third quarter of calendar year 2022.

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T [phone] [e-mail] W www.resapphealth.com.au

For personal use only

ResAppDx is now live on major telehealth platforms in Switzerland (Medgate), Australia (Coviu, Phenix Health and Doctors on Demand) and Indonesia (Alodokter). ResApp continues to have discussions with several additional telehealth providers globally.

Pre-submission meeting with the US FDA

In January, ResApp held a pre-submission meeting with the US Food and Drug Administration (FDA) to progress the clearance of a prescription-only software as medical device application to detect lower respiratory tract illness in children and adults. During the meeting ResApp received feedback from the FDA on potential approval pathways for the application and other requirements. ResApp expects to continue to engage with the FDA through additional pre-submission meetings to progress clearance.

COVID-19 RESEARCH PROGRAM

Positive results for detecting COVID-19 using a new cough audio-based algorithm

During the quarter, ResApp announced positive results for a new novel cough audio-based COVID-19 screening test that only requires a smartphone. In a pilot clinical trial of 741 patients,

ResApp's screening test was found to correctly detect COVID-19 (sensitivity) in 92% of people with infection. The test was found to correctly identify patients who don't have COVID-19 with 80% specificity. In a population where 5% of individuals are positive for the virus, the test had a negative predictive value of 99.5%, meaning that people who receive a negative test result are almost certainly truly negative and may not require a follow-on rapid antigen or PCR test.

To ensure that the algorithm was specific to COVID-19 it was also tested against ResApp's Breathe Easy pre-COVID-19 dataset. This dataset included patients with a variety of non-COVID-19 related acute and chronic respiratory conditions. The algorithm achieved greater than 90% specificity for these patients.

This reported performance was obtained using K-fold cross-validation to provide an estimate of performance on unseen data. ResApp is now progressing a validation study of the algorithms by recruiting additional patients in India and the United States to confirm the cross-validation results.

ResApp is preparing documentation to engage with regulators globally to confirm pathways for regulatory approval and, in parallel, is in discussions with multiple sites for a blinded prospective study with results to be used for regulatory submissions.

SLEEP APNOEA SCREENING

Update on SleepCheckRx US FDA 510(k) premarket notification submission

In October 2021, ResApp submitted a 510(k) premarket notification submission to the US FDA for SleepCheckRx, a prescription-only, software as a medical device smartphone application for at-home sleep apnoea screening. In December, ResApp received a request for additional information from the FDA and ResApp held a meeting with the FDA to clarify this request in January. ResApp is preparing its response to the FDA's request for additional information and expects to submit a response to the FDA in June.

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T [phone] [e-mail] W www.resapphealth.com.au

COMPANY

For personal use only

Proposed acquisition of ResApp by Pfizer

In April, ResApp announced that it had entered into a binding scheme implementation deed with Pfizer Australia Holdings Pty Limited (a wholly owned subsidiary of Pfizer Inc, a global biopharmaceutical company) under which it is proposed that Pfizer will acquire 100% of the shares in ResApp Health by way of a Scheme of Arrangement for $0.115 per share in cash, representing a total equity value of approximately $100 million. The consideration represents a 27.8% premium to the closing price of ResApp shares on the last trading day prior to announcement of the scheme

Subject to the Independent Expert determining that the Scheme is in the best interests of ResApp shareholders, and in the absence of a superior proposal, the Directors of ResApp unanimously recommend that ResApp shareholders vote in favour of the Scheme and intend to vote shares in their control in favour of the proposed Scheme.

ResApp is presently preparing a Scheme Booklet which will contain information related to the Scheme, including the reasons for the Directors' recommendation and details of the Scheme Meeting. The Scheme Booklet will also include an Independent Expert's opinion on whether the

Scheme is in the best interests of ResApp shareholders. The Scheme Booklet is expected to be sent to ResApp shareholders in mid-May 2022. The Scheme Meeting expected to be held in mid-

June 2022.

R&D License Agreement with Pfizer

In parallel, ResApp entered into a six-month research and development (R&D) licence agreement with Pfizer to collaborate on the R&D of products in the field of COVID-19. This licence agreement includes a $3 million upfront license fee and up to $1 million in milestone payments. ResApp has provided Pfizer a right of first negotiation for certain commercial transactions with third parties (including commercialisation licences) in the COVID-19 field.

SECOND QUARTER FINANCIAL RESULTS

Receipts from customers for the quarter totalled $178,000 (Q2: $124,000), which comprised of payments from customers for SleepCheck downloads and ResAppDx use, and additional advanced payments from Janssen.

Overall cash decrease was $1,706,000 (Q2: $1,062,000), with net cash used in operating activities totalling $1,577,000 (Q2: $969,000). Research and development payments decreased to $410,000 (Q2: $697,000) due to the completion of the US and India COVID-19 studies during the quarter. Advertising and marketing costs increased to $70,000 (Q2: $36,000). Staff costs remained constant at $1,018,000 (Q2: $1,068,000). The company made payments of $152,000 to directors during the period ($32,000 for non-executive director fees and $120,000 for executive director fees).

ResApp retained a cash balance of $1.7 million at the end of the quarter. ResApp expects to shortly receive the $3 million upfront license fee from the Pfizer research and development

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T [phone] [e-mail] W www.resapphealth.com.au

For personal use only

agreement and also may receive up to an additional $1 million in milestone payments during the quarter.

MANAGEMENT COMMENTARY

CEO and Managing Director Dr Tony Keating said: "In January, we were excited to see the launch of ResAppDx on two additional telehealth platforms - Alodokter in Indonesia and Doctors on Demand in Australia. We are now reaching a large number of doctors and patients with ResAppDx and hope to continue to see growth in use. It is through this growth that we will build trust and confidence in our product which will drive further adoption.

"We were delighted to announce in March that we had achieved positive results from our COVID-19 program. The ability to use a smartphone-based screening test to rapidly rule-out COVID-19 infection in large numbers of people would provide many benefits. By reducing the number of rapid antigen or PCR tests required, we may be able to substantially reduce costs, increase reach (identify more positive infections than before) and reduce the environmental impact of traditional testing.

"We are also excited by the proposed acquisition by Pfizer. The proposal recognises the years of dedicated work by our team to build ResApp into a leader in audio-based analysis of respiratory health. It represents a great validation of our technology and the benefits it brings to patients and clinicians. The board of ResApp considers the price offered to be an attractive premium to the pre-announcement share price and combined with the certainty of an all-cash offer, the proposal represents an attractive option for shareholders."

CONFERENCE CALL DETAILS

Shareholders are invited to join a conference call hosted by Managing Director and CEO, Dr Tony Keating at 10:00am Australian Eastern Standard Time (AEST) today. Shareholders can pre-register for the call by following the link below. Registered participants will receive a calendar notification with dial-in details and a PIN to access the call.

https://s1.c-conf.com/diamondpass/10021642-hbj520.html

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and

SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visitwww.resapphealth.com.au.

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T [phone] [e-mail] W www.resapphealth.com.au

For personal use only

Contacts
Dr Tony Keating	Mr Brian Leedman
CEO and Managing Director	Executive Director, Corporate Affairs
[phone]	[phone]
[e-mail]	[e-mail]

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T [phone] [e-mail] W www.resapphealth.com.au